CJC-1295 (no DAC) + Ipamorelin

Fat LossGHRH + GHS combinationExperimental

Research blend combining a GHRH analog (usually Mod GRF / CJC no DAC) with ipamorelin to stimulate GH via two receptor classes. Not FDA-approved. Both components are WADA S2.

Calculate Dose

For research use only.

Key Facts

CAS: N/A (blend)
Molecular Weight (MW): Varies
Half-life: CJC: ~30 min; Ipa: ~2 hours
Unit: mcg
Administration Route: Subcutaneous
Frequency: 1-2x daily
Last updated: 8/23/2026
Targets: GHRH receptorGHSR (ghrelin receptor)

Overview

Research blend combining a GHRH analog (usually Mod GRF / CJC no DAC) with ipamorelin to stimulate GH via two receptor classes. Not FDA-approved. Both components are WADA S2.

Protocol

Dosage Range: 100-200 mcg each
Frequency: 1-2x daily
Cycle: 8-12 weeks on, 4 weeks off
Administration Route: Subcutaneous
Reconstitution Guide: 3 mL BAC for 6mg/12mg blend

Science

Mechanism of Action

GHRH-receptor agonism plus ghrelin-receptor (GHSR) agonism can produce synergistic GH release compared with either secretagogue alone in experimental settings.